Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Taebo Sim

Showing results (111-120 of 121) with videos related to

Pageof 13
Sort By:
Cell Chemical Biology|March 26, 2019
Development of a Selective CDK7 Covalent Inhibitor Reveals Predominant Cell-Cycle PhenotypeCalla M Olson, Yanke Liang, Alan Leggett, et al.
Journal of Enzyme Inhibition and Medicinal Chemistry|April 29, 2022
Identification of highly selective type II kinase inhibitors with chiral peptidomimetic tailsSeo-Jung Han, Jae Eun Jung, Do Hee Oh, et al.
Theranostics|September 18, 2025
Targeted autophagic clearance of Tau protects against Alzheimer's disease through amelioration of Tau-mediated lysosomal stressBo Hyun Yoon, Jinho Kim, Sandip Sengupta, et al.
Journal of Medicinal Chemistry|January 14, 2022
Novel Macrocyclic Peptidomimetics Targeting the Polo-Box Domain of Polo-Like Kinase 1SeongShick Ryu, Jung-Eun Park, Young Jin Ham, et al.
Blood|March 20, 2010
Discovery of a small-molecule type II inhibitor of wild-type and gatekeeper mutants of BCR-ABL, PDGFRalpha, Kit, and Src kinases: novel type II inhibitor of gatekeeper mutantsEllen Weisberg, Hwan Geun Choi, Arghya Ray, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 29, 2014
Development of covalent inhibitors that can overcome resistance to first-generation FGFR kinase inhibitorsLi Tan, Jun Wang, Junko Tanizaki, et al.
Nature|July 22, 2014
Targeting transcription regulation in cancer with a covalent CDK7 inhibitorNicholas Kwiatkowski, Tinghu Zhang, Peter B Rahl, et al.
ACS Chemical Biology|August 14, 2018
Structural and Atropisomeric Factors Governing the Selectivity of Pyrimido-benzodiazipinones as Inhibitors of Kinases and BromodomainsJinhua Wang, Tatiana Erazo, Fleur M Ferguson, et al.
Nature|January 15, 2010
Targeting Bcr-Abl by combining allosteric with ATP-binding-site inhibitorsJianming Zhang, Francisco J Adrián, Wolfgang Jahnke, et al.
Cell|December 4, 2020
Mapping the Degradable Kinome Provides a Resource for Expedited Degrader DevelopmentKatherine A Donovan, Fleur M Ferguson, Jonathan W Bushman, et al.
Pageof 13

Showing results (111-120 of 121) with videos related to

Sort By:
Pageof 13
Cell Chemical Biology|March 26, 2019
Development of a Selective CDK7 Covalent Inhibitor Reveals Predominant Cell-Cycle PhenotypeCalla M Olson, Yanke Liang, Alan Leggett, et al.
Journal of Enzyme Inhibition and Medicinal Chemistry|April 29, 2022
Identification of highly selective type II kinase inhibitors with chiral peptidomimetic tailsSeo-Jung Han, Jae Eun Jung, Do Hee Oh, et al.
Theranostics|September 18, 2025
Targeted autophagic clearance of Tau protects against Alzheimer's disease through amelioration of Tau-mediated lysosomal stressBo Hyun Yoon, Jinho Kim, Sandip Sengupta, et al.
Journal of Medicinal Chemistry|January 14, 2022
Novel Macrocyclic Peptidomimetics Targeting the Polo-Box Domain of Polo-Like Kinase 1SeongShick Ryu, Jung-Eun Park, Young Jin Ham, et al.
Blood|March 20, 2010
Discovery of a small-molecule type II inhibitor of wild-type and gatekeeper mutants of BCR-ABL, PDGFRalpha, Kit, and Src kinases: novel type II inhibitor of gatekeeper mutantsEllen Weisberg, Hwan Geun Choi, Arghya Ray, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 29, 2014
Development of covalent inhibitors that can overcome resistance to first-generation FGFR kinase inhibitorsLi Tan, Jun Wang, Junko Tanizaki, et al.
Nature|July 22, 2014
Targeting transcription regulation in cancer with a covalent CDK7 inhibitorNicholas Kwiatkowski, Tinghu Zhang, Peter B Rahl, et al.
ACS Chemical Biology|August 14, 2018
Structural and Atropisomeric Factors Governing the Selectivity of Pyrimido-benzodiazipinones as Inhibitors of Kinases and BromodomainsJinhua Wang, Tatiana Erazo, Fleur M Ferguson, et al.
Nature|January 15, 2010
Targeting Bcr-Abl by combining allosteric with ATP-binding-site inhibitorsJianming Zhang, Francisco J Adrián, Wolfgang Jahnke, et al.
Cell|December 4, 2020
Mapping the Degradable Kinome Provides a Resource for Expedited Degrader DevelopmentKatherine A Donovan, Fleur M Ferguson, Jonathan W Bushman, et al.
Pageof 13